Olesoxime is a small cholesterol-like molecule that was discovered in a screening program aimed at finding treatment for amyotrophic lateral sclerosis and other diseases where motor neurons degenerate. In addition to its neuroprotective and pro-regenerative effects on motor neurons in vitro and in vivo, it has been shown to have analgesic effects in rat models of painful peripheral neuropathy due to vincristine and diabetes. We used a rat model of painful peripheral neuropathy produced by the chemotherapeutic agent, paclitaxel, to determine whether olesoxime could reverse established neuropathic pain. In addition, we determined whether giving olesoxime during the exposure to paclitaxel could prevent the development of the neuropathic pain syndrome and the accompanying degeneration of the terminal arbors of sensory fibers in the epidermis. Olesoxime significantly reduced established mechano-allodynia and mechano-hyperalgesia. There was no indication of tolerance to the effect during five days of dosing and the analgesia persisted for 5-10 days after the last injection. Giving olesoxime during the exposure to paclitaxel significantly and permanently reduced the severity of mechano-allodynia and mechano-hyperalgesia and significantly reduced the amount of sensory terminal arbor degeneration. Olesoxime targets mitochondrial proteins and its effects are consistent with the mitotoxicity hypothesis for paclitaxelevoked painful peripheral neuropathy. We conclude that olesoxime may be useful clinically for both the prevention and treatment of paclitaxel-evoked painful peripheral neuropathy. Ó
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Introduction
Olesoxime (cholest-4-en-3-one, oxime; TRO19622) is a small (molecular weight: 399) cholesterol-like compound with neuroprotective, pro-regenerative, and analgesic actions. In vitro, olesoxime promotes survival and stimulates neurite outgrowth of motor neurons cultured in the absence of neurotrophic factors [2] . In vivo, olesoxime improves motor performance and increases survival in a mouse model of familial amyotrophic lateral sclerosis [2] . It also promotes axonal regeneration after sciatic nerve crush in adult mice, prevents the death of motor neurons following axotomy in neonatal rats, and improves motor nerve conduction velocity deficits in diabetic rats [2, 3] . In addition, olesoxime reverses mechano-allodynia in rats with painful peripheral neuropathy due to vincristine treatment or streptozotocin-induced diabetes [3] . However, olesoxime has no effect on pain sensitivity in normal animals, no effect in the CCI model of post-traumatic painful peripheral neuropathy, and no effect on Phase I or II responses in the formalin test. It is not an anti-convulsant or a sedative [3] .
Work with an animal model of the painful peripheral neuropathy produced by the chemotherapeutic agent, paclitaxel, has shown that the condition is characterized by an increased incidence of swollen and vacuolated axonal mitochondria, degeneration of the intraepidermal terminal arbors of sensory axons, and an abnormal spontaneous discharge in sensory afferents. It has been hypothesized that the degeneration, abnormal discharge, and pain are all secondary to paclitaxel-evoked dysfunction in axonal mitochondria [9] [10] [11] 21, 22, 26] .
Paclitaxel is known to have direct effects on mitochondria. It increases conductance through the mitochondrial permeability transition pore (mPTP), a channel that spans the mitochondrial inner membrane and opens when mitochondria are damaged by excessive calcium, ADP and ATP depletion, and oxidative stress [1, 7, 12, 15, 23] . mPTP opening is involved in both necrotic and apoptotic cell death. Paclitaxel's effect on mPTP may be mediated 
